Here are 1-2 brief analogies for Oncolytics Biotech (ONCY):

• A Moderna, but specializing in using viruses to fight cancer.
• A Vertex Pharmaceuticals, but focused on developing breakthrough virus-based therapies for cancer.

• Pelareorep: An intravenously delivered immunotherapeutic oncolytic virus designed to selectively replicate in cancer cells and stimulate an anti-cancer immune response.

Oncolytics Biotech (ONCY) is a clinical-stage biotechnology company focused on the development of its lead investigational therapeutic, pelareorep, for cancer treatment. As a company in the research and development phase, it does not currently have commercialized products and therefore does not have major "customers" in the traditional sense of selling goods or services to individuals or other companies.

Instead, Oncolytics Biotech's primary business activities involve conducting clinical trials and partnering with larger pharmaceutical companies for drug development and potential future commercialization. While these are collaborations rather than direct sales of a finished product, these partnerships represent its most significant engagements with other companies, critical to its development strategy.

Therefore, interpreting the prompt to identify the major companies with which Oncolytics Biotech primarily engages in its business strategy, the key partners are:

• Roche (OTCQX: RHHBY) - Partner in clinical trials, for example, supplying atezolizumab (Tecentriq) for combination studies with pelareorep.
• Pfizer (NYSE: PFE) and Merck KGaA (OTCQX: MKGAY) - Collaborators in clinical trials that combined pelareorep with avelumab (Bavencio), which is co-developed and co-commercialized by Pfizer and Merck KGaA.

Jared Kelly, Chief Executive Officer & Director

Jared Kelly was appointed Chief Executive Officer and a member of the Board of Directors in June 2025. He is described as a successful biotech executive with expertise in transformative deals and corporate strategy. Most recently, he played a central role in orchestrating the sale of Ambrx Biopharma to Johnson & Johnson for $2 billion. Before his time at Ambrx, Mr. Kelly advised several leading-edge biotech companies on M&A and licensing transactions while working at respected law firms, including Lowenstein Sandler LLP and Kirkland & Ellis LLP. He holds a JD and LLM from Georgetown Law.

Kirk Look, CA, MSJ, Chief Financial Officer

Kirk Look has served as the Chief Financial Officer of Oncolytics Biotech since November 2012. He joined the company in April 2003 as Controller. Mr. Look is a Chartered Accountant with over two decades of experience in accounting, finance, tax, and treasury. Prior to joining Oncolytics, he was a Manager of Audit and Assurance Services with Ernst & Young LLP in Canada from 2000 to April 2003, and held positions as Audit Manager and Senior Accountant at Ernst & Young LLP in Chile from 1998 to 1999. He earned a Bachelor of Commerce from the University of Calgary and a Master of Science in Jurisprudence Law Degree from Seton Hall Law School.

Thomas C. Heineman, MD, PhD, Chief Medical Officer

Dr. Thomas C. Heineman became the Chief Medical Officer of Oncolytics Biotech in 2021. His previous roles include Senior Vice President and Head of Clinical Development at Denovo Biopharma. He also served as Vice President and Head of Clinical Development at both Genocea Biosciences and Halozyme Therapeutics, and as Senior Director of Global Clinical Research and Development at GlaxoSmithKline.

Allison Hagerman, PEng, PMP, MBT, Vice President, Product Development

Allison Hagerman holds the position of Vice President, Product Development at Oncolytics Biotech and has been part of senior management since 2010.

Andrew Aromando, Chief Business Officer

Andrew Aromando was appointed Chief Business Officer in June 2025. He brings over 30 years of experience in the life sciences industry, including more than 20 years in C-level positions at prominent oncology-focused biopharma companies and global service providers. Mr. Aromando is a former executive at Ambrx Biopharma.

Pelareorep Addressable Markets

• Pancreatic Cancer (specifically metastatic pancreatic ductal adenocarcinoma - mPDAC):
  • The global pancreatic cancer therapeutics market is projected to exceed $2.5 billion by 2030, growing at a 6.5% CAGR.
  • Another estimate places the global pancreatic cancer market size at approximately $6 billion in 2023, expected to expand to $36 billion by the end of 2036, at an ~18% CAGR.
  • The pancreatic cancer treatment market is also projected to reach $10.2 billion by 2034, with a 12.4% CAGR.
  • A different report forecasts the pancreatic cancer treatment market size to grow to $6.85 billion by 2029, showing a CAGR of 15.7% from 2022 to 2029. North America held a significant share of this global market, at 46.97% in 2022.
  • For first-line mPDAC, a total addressable market of $3 billion with a 15% CAGR to 2032 is noted, encompassing 500,000 patients globally.
• Metastatic Breast Cancer (specifically HR+/HER2- metastatic breast cancer):
  • The metastatic breast cancer treatment market is forecast to grow at a CAGR of 10.4% from 2021 to 2030, reaching $41.74 billion globally.
  • Drug-treatable HR+/HER2- breast cancer cases are projected to increase to nearly 300,000 patients by 2028 across the U.S., major European markets, and Japan.
  • The projected size of the global breast cancer drug market by 2030 is $63.9 billion, with nearly 10% annual growth.
• Multiple Myeloma (a hematological malignancy):
  • The global multiple myeloma therapeutics market size reached $22.6 billion in 2024, with projections to expand at a CAGR of 6.8% from 2025 to 2033, reaching $43.5 billion by 2033.
  • Another estimation for the global multiple myeloma market size is $27.75 billion in 2024, projected to grow to $49.89 billion by 2034 at a compound annual growth rate (CAGR) of 6.04%. North America was the dominant region in 2024.

Expected Drivers of Future Revenue Growth for Oncolytics Biotech (ONCY)

• Advancement and Potential Approval in Metastatic Breast Cancer (HR+/HER2-): Oncolytics Biotech's lead candidate, pelareorep, has demonstrated substantial clinical benefit in two randomized Phase 2 studies for HR+/HER2- metastatic breast cancer, which is a top priority for the company. The company aims to approximate these benefits in a planned registration-enabling study, with the potential for accelerated approval submission based on progression-free survival (PFS) benefits.
• Advancement and Potential Approval in Pancreatic Cancer (mPDAC): Pelareorep has shown transformative survival data in metastatic pancreatic ductal adenocarcinoma (mPDAC), with pelareorep-based regimens achieving a 21.9% two-year overall survival rate in first-line mPDAC patients, significantly outperforming historical benchmarks. The company is in active discussions with the U.S. Food and Drug Administration (FDA) to finalize pivotal study parameters for a registration-enabling trial, with potential initiation by Q4 2025. Pelareorep has also been granted Fast Track designation by the FDA for advanced/metastatic pancreatic ductal adenocarcinoma.
• Advancement and Potential Approval in Anal Cancer (SCAC): Interim results from the GOBLET trial's Cohort 4, investigating pelareorep in combination with atezolizumab in second-line squamous cell carcinoma of the anal canal (SCAC), have shown a promising 33% overall response rate. This indicates a meaningful signal in a difficult-to-treat indication with limited options, potentially leading to further development and a future commercial opportunity.
• Strategic Partnerships and Collaborations: Oncolytics is actively pursuing partnerships to advance the development of pelareorep across various indications. The company has teamed up with pharmaceutical industry collaborators such as Roche Holding AG, Pfizer Inc., Merck Serono, Incyte Corporation, and Adlai Nortye to evaluate pelareorep in combination with therapeutic agents. These collaborations can provide funding, shared development costs, and broader market access, contributing to future revenue.
• Expansion into Additional Gastrointestinal (GI) Cancers: The ongoing GOBLET trial is evaluating pelareorep across multiple gastrointestinal cancers, suggesting a platform potential beyond pancreatic and anal cancers. The company continues to generate compelling efficacy signals in various GI cancers, which could lead to exploring additional registrational programs.

Share Issuance

• Oncolytics Biotech entered into a strategic share purchase agreement with Alumni Capital LP in April 2025, providing access to up to US$20 million in funding over a 15-month period. Under this agreement, Oncolytics can sell common stock to Alumni at market-based prices, maintaining control over the timing and amount of sales. The company issued 816,326 initial commitment shares to Alumni and may issue an additional 816,326 shares pro rata upon purchase notices.
• In October 2025, Oncolytics Biotech established a new at-the-market (ATM) equity financing agreement with BTIG, LLC, enabling the company to sell up to $50 million in common stock.
• An earlier at-the-market (ATM) equity offering sales agreement was initiated in June 2020 with Canaccord Genuity, allowing Oncolytics to raise up to $40 million over 25 months by issuing common shares at prevailing market prices.

Inbound Investments

• Oncolytics Biotech secured a flexible US$20 million funding commitment through a share purchase agreement with Alumni Capital LP in April 2025, aimed at funding the clinical development of pelareorep. Alumni Capital is listed as an institutional investor in Oncolytics Biotech.
• The company received a $5 million grant from the Pancreatic Cancer Action Network (PanCAN) to fund Cohort 5 of the GOBLET trial, which is enrolling newly diagnosed metastatic pancreatic cancer patients.